UGA researchers develop oral drug candidate targeting drug-resistant malaria
Researchers from the University of Georgia (UGA) and the University of Illinois Chicago have developed a new oral antimalarial drug candidate that could help address drug-resistant malaria.
The compound was developed by a team led by Belen Cassera at UGA, following more than a decade of research into new treatments for parasitic diseases.
The researchers screened and refined nearly 1,500 molecules before identifying the new candidate.
The drug is designed to target the blood stage of malaria, when symptoms usually develop and parasites can also be transmitted through mosquitoes.
Laboratory research suggests that the compound can kill malaria parasites and prevent them from entering a dormant state that can allow them to survive treatment and contribute to drug resistance.
The candidate has also shown potential for use as a single-dose treatment, although further studies are needed to confirm its effectiveness and safety.
Researchers are now planning additional testing in cells and animals to assess safety, potential adverse effects and appropriate dosing before the compound can progress towards human clinical trials.
The research involves several institutions, including the University of Illinois Chicago, Molstoft, Portland State University, the University of Dundee and Medicines for Malaria Venture. Patents covering the drug molecule have also been filed.
